Vaxcyte 

Vaxcyte 

Yahoo Finance • 12 days ago

If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone

Quick Read Baupost dumped all 800,000 PCVX shares and 893,126 WTW shares by June 30, weeks before retail investors learned Klarman had held either. 13F filings run 45 days stale, so retail investors who copied Klarman's disclosed PCVX sta... Full story

Yahoo Finance • 2 months ago

Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following in... Full story

Yahoo Finance • 2 months ago

Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 2, Vaxcyte, Inc. (NASDAQ:PCVX) dosed the first participant in its Phase 1 first-in-human clinical trial of VAX-A1. VAX-A1... Full story

Yahoo Finance • 2 months ago

Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money. On June 3, Vaxcyte Inc. (NASDAQ:PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1. Thi... Full story

Yahoo Finance • 3 months ago

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Pivotal bioVenture Partners Investment Advisor increased its position in Trevi Therapeutics(NASDAQ:TRVI) during the first quarter, acquiring 296,944 shares in an estimated $3.32 million trade based on average quarterly pricing, according t... Full story

Yahoo Finance • 3 months ago

How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study. Continue Reading... Full story

Yahoo Finance • 3 months ago

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Key Points Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million. Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales an... Full story

Yahoo Finance • 5 months ago

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, to... Full story

Yahoo Finance • 5 months ago

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte, Inc. OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive® (PCV21) and Prevna... Full story

Yahoo Finance • 5 months ago

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SE... Full story

Yahoo Finance • 5 months ago

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story

Yahoo Finance • 5 months ago

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story

Yahoo Finance • 5 months ago

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals(NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pric... Full story

Yahoo Finance • 5 months ago

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority T... Full story

Yahoo Finance • 6 months ago

Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)

Vaxcyte Incorporated (NASDAQ:PCVX) is one of the 17 biotechnology stocks with more than 50% upside. On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued progress a... Full story

Yahoo Finance • 7 months ago

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Vaxcyte, Inc. Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferi... Full story

Yahoo Finance • 7 months ago

Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Vaxcyte (NasdaqGS:PCVX) has completed a major public equity offering, adding fresh capital to it... Full story

Yahoo Finance • 8 months ago

What Makes Vaxcyte (PCVX) So Attractive

Vaxcyte Inc. (NASDAQ:PCVX) is one of the most promising mid-cap healthcare stocks under $50. On December 9, BTIG analyst Thomas Shrader reiterated his bullish view of Vaxcyte Inc. (NASDAQ:PCVX). He assigned a Buy rating to the stock with... Full story

Yahoo Finance • 9 months ago

Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best biotech stocks to buy, according to Wall Street analysts. On December 8, the company confirmed the dosing of the first patients in its Phase 3 OPUS trial. The company is evaluating VAX-31 in t... Full story

Yahoo Finance • 9 months ago

These stocks are new additions to Mizuho’s ’Americas Top Picks’ list

Investing.com -- Mizuho has refreshed its monthly Americas Top Picks list, adding new high-conviction ideas selected by its U.S. equity analysts. The list highlights “our analysts’ highest conviction, catalyst-driven ideas,” Mizuho says,... Full story